Integrins are a large family of heterodimeric transmembrane cell adhesion receptors (1). They are involved in many aspects of cell behavior and are known to regulate a number of intracellular signaling pathways (2-4). One of the key integrin functions is an adhesion-mediated growth signaling (5). Integrin-mediated positive cell growth signaling cascade leads to activation of MAP 1 kinases, which serves as a hallmark of cell proliferation (6 -9). Integrins can synergize with growth factor receptors to relay the control of cell cycle progression in adhesiondependent cell types (5, 10). Adhesion of different cell types to certain ECM proteins can either trigger proliferation or switch them to a differentiation program (11, 12). These opposite responses are possible due to redundant and overlapping expression of integrins and are mediated by ligation of different integrin ␣␤ heterodimers on the cell surface (1). Differential coupling of the Shc adapter protein to integrin ␣ subunits causes selective activation of the MAP kinase cascade in adherent cells (13). This allows various integrin ␣␤ heterodimers to transduce distinct signals from the ECM to the cell interior, including positive and negative growth signals in response to adhesion. ␤ 1 integrin, the most ubiquitous ␤ subunit, pairs with at least 10 different ␣ subunits to comprise receptors for a wide variety of ECM proteins. It is abundantly expressed in vivo on all proliferating as well as differentiated growth-arrested cell types, excluding red blood cells (1). ␤ 1 integrin is known to be involved in cell growth regulation in many cell types (14, 15) . Four cytoplasmic domain variants generated by alternative splicing have been described for the ␤ 1 subunit (Refs. 16 -21 and reviewed in Ref. 22). In most cell types ␤ 1 integrin is represented predominantly by the ␤ 1 A isoform. The only noticeable exception is in differentiated striated muscles where it is displaced by the ␤ 1 D integrin isoform (16). The other two minor ␤ 1 integrin variants with the alternatively spliced cytoplasmic domains, ␤ 1 B and ␤ 1 C, were identified several years ago (18 -21). Unlike ␤ 1 D integrin, these two isoforms are always coexpressed at low levels with the major ␤ 1 A isoform (18, 19, 21) . Recently, the ␤ 1 C isoform has been shown to inhibit strongly cell growth upon transient expression in 10T1/2 fibroblasts (23). A short amino acid sequence Gln 795 -Gln 802 within the cytoplasmic domain is essential for ␤ 1 C-mediated growth arrest and is apparently unique for this integrin (24).
Integrins are a large family of heterodimeric transmembrane cell adhesion receptors (1) . They are involved in many aspects of cell behavior and are known to regulate a number of intracellular signaling pathways (2) (3) (4) . One of the key integrin functions is an adhesion-mediated growth signaling (5) . Integrin-mediated positive cell growth signaling cascade leads to activation of MAP 1 kinases, which serves as a hallmark of cell proliferation (6 -9) . Integrins can synergize with growth factor receptors to relay the control of cell cycle progression in adhesiondependent cell types (5, 10) . Adhesion of different cell types to certain ECM proteins can either trigger proliferation or switch them to a differentiation program (11, 12) . These opposite responses are possible due to redundant and overlapping expression of integrins and are mediated by ligation of different integrin ␣␤ heterodimers on the cell surface (1) . Differential coupling of the Shc adapter protein to integrin ␣ subunits causes selective activation of the MAP kinase cascade in adherent cells (13) . This allows various integrin ␣␤ heterodimers to transduce distinct signals from the ECM to the cell interior, including positive and negative growth signals in response to adhesion. ␤ 1 integrin, the most ubiquitous ␤ subunit, pairs with at least 10 different ␣ subunits to comprise receptors for a wide variety of ECM proteins. It is abundantly expressed in vivo on all proliferating as well as differentiated growth-arrested cell types, excluding red blood cells (1) . ␤ 1 integrin is known to be involved in cell growth regulation in many cell types (14, 15) . Four cytoplasmic domain variants generated by alternative splicing have been described for the ␤ 1 subunit (Refs. 16 -21 and reviewed in Ref. 22 ). In most cell types ␤ 1 integrin is represented predominantly by the ␤ 1 A isoform. The only noticeable exception is in differentiated striated muscles where it is displaced by the ␤ 1 D integrin isoform (16) . The other two minor ␤ 1 integrin variants with the alternatively spliced cytoplasmic domains, ␤ 1 B and ␤ 1 C, were identified several years ago (18 -21) . Unlike ␤ 1 D integrin, these two isoforms are always coexpressed at low levels with the major ␤ 1 A isoform (18, 19, 21) . Recently, the ␤ 1 C isoform has been shown to inhibit strongly cell growth upon transient expression in 10T1/2 fibroblasts (23) . A short amino acid sequence Gln 795 -Gln 802 within the cytoplasmic domain is essential for ␤ 1 C-mediated growth arrest and is apparently unique for this integrin (24) .
Striated muscle myoblasts become irreversibly withdrawn from the cell cycle early in myodifferentiation before cell fusion occurs. The timing of cell cycle withdrawal (commitment to myodifferentiation) coincides with the appearance of musclespecific ␤ 1 D integrin in myocyte cultures and is in accordance with its increased expression in postmitotic growth-arrested myoblasts (16) . We hypothesized that ␤ 1 D might transmit a growth inhibitory signal in normal myoblasts in vivo. Here we demonstrate an inhibition of cell proliferation by ␤ 1 D integrin when it is expressed transiently in normal myoblasts and fibroblasts.
MATERIALS AND METHODS
Antibodies and Reagents-Thymidine analog bromodeoxyuridine (BrdUrd) and mouse anti-BrdUrd mAb were from Sigma. Mouse mAb TS2/16 against human ␤ 1 integrin was provided by Dr. Martin Hemler (Dana Farber Cancer Institute, Boston) and used to detect the injected or transfected ␤ 1 A and ␤ 1 D integrins. Hamster anti-mouse ␤ 1 mAb HM␤1-1 for visualization of the endogenous ␤ 1 integrin was received from PharMingen (San Diego, CA). Anti-MAP kinase rabbit polyclonal antibody sc-93 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and was used for MAP kinase immunoprecipitation. Antibody against active (dually phosphorylated) MAP kinases was from Promega (Madison, WI). Rabbit polyclonal antibodies reacting with mouse cyclins A and E were obtained from Rockland (Gilbertsville, PA). Mouse mAb 7G7B6 against interleukin-2 receptor (IL2R) extracellular domain was from ATCC (Rockville, MD). Hamster mAbs reacting with mouse ␣ 1 , ␣ 2 , and ␣ 5 integrins were obtained from PharMingen. Antibody against ␣ 3 integrin cytoplasmic domain was kindly provided by Dr. Guido Tarone (University of Torino, Italy). Isoform-specific anti-␤ 1 A and anti-␤ 1 D antibodies were characterized previously (16) .
Cell Cultures-Mouse C2C12 myoblasts and NIH 3T3 fibroblasts were obtained from ATCC and used between 3 and 10 passages. Ha-(12R)Ras-and (⌬22W)Raf-transfected NIH 3T3 fibroblasts were described previously (25) (26) (27) (28) . Briefly, activated Ha-(12R)Ras and activated (⌬22W)Raf-1 (25, 26) were cloned into the expression vector pZIP-NeoSV(ϫ)1 and transfected into NIH 3T3 cells using the calcium phosphate precipitation technique essentially as reported previously (25, 27) . 24 h after transfection G418 was added to the growth medium at 1 mg/ml. The cells were selected for 10 days by which time all the cells in a control mock-transfected dish were dead. NIH 3T3 cells stably expressing Ha-(12R)Ras or (⌬22W)Raf-1 displayed very similar highly transformed phenotype as detected by cell morphology, inhibited spreading, colony formation in soft agar, and profound cytoskeletal changes (26, 28) . Rat embryo fibroblast line REF 52 was described previously (29) . ␤ 1 A-CHO and ␤ 1 D-CHO stable transfectants were characterized previously (16, 17) .
cDNA Constructs, Microinjection, and Transfection-The cDNAs for human ␤ 1 A and ␤ 1 D cytoplasmic domain isoforms in pECE vector were described previously (16, 19) . cDNAs encoding ␤ 1 A/␤ 1 D chimeras were prepared using the ␤ 1 A and ␤ 1 D cDNA fragments and polymerase chain reaction-based mutagenesis. The sequences of the four mutant ␤ 1 A/␤ 1 D integrin cDNAs were verified by dideoxy termination sequencing. IL2R (interleukin 2 receptor) cDNA and IL2R-␤ 1 A chimera (30) were kindly provided by Dr. Susan LaFlamme (Albany Medical College, Albany, NY). IL2R-␤ 1 D chimera was generated using polymerase chain reaction amplification of the 3Ј end of the ␤ 1 D cDNA (16) with the forward primer 5Ј-TGTAGCTGGTGTGGTTGCTG-3Ј and the reverse primer 5Ј-TTCAAAGCTATTCTGGGCTG-3Ј. The polymerase chain reaction fragment was digested with HindIII endonuclease, and the resulting fragment encoding the ␤ 1 D cytoplasmic domain was inserted in the HindIII site of the IL2R-␤ 1 A plasmid (30) to generate a plasmid encoding the IL2R-␤ 1 D chimera. The structure of the IL2R-␤ 1 D construct was confirmed by dideoxynucleotide sequence analysis using a primer upstream of the cloning site (5Ј-AGCGTCCTCCTCCTGAGTG-3Ј).
For nuclear microinjections the ␤ 1 A and ␤ 1 D integrin cDNAs were used at 0.5 mg/ml to inject C2C12 myoblasts, REF 52 fibroblasts, or NIH 3T3 cells growing on fibronectin-coated glass coverslips (23 Integrin Analysis by Flow Cytometry-The expression levels of the transfected human ␤ 1 A and ␤ 1 D integrins were determined using fluorescence-activated cell sorter analysis with TS2/16 mAb which reacts identically with these two ␤ 1 cytoplasmic domain variants (16, 17) . The transfectants were incubated with 10 g/ml of TS2/16 mAb for 1 h at 4°C followed by fluorescein-labeled goat anti-mouse IgG. After the staining, cells were analyzed in a FACScan® flow cytometer (Becton Dickinson, Mountain View, CA).
Cell Proliferation Assay-The cell proliferation assay based on BrdUrd incorporation into the nuclei was described earlier (23, 31) . Cells transfected with ␤ 1 A, ␤ 1 D cDNAs, ␤ 1 A/␤ 1 D chimeras, or IL2R-␤ 1 A and IL2R-␤ 1 D constructs were trypsinized on the day after transfection and were plated on fibronectin-coated glass coverslips in DMEM containing 10% FBS. The next day, the growth medium was replaced for DMEM with 0.5% FBS and cells were kept in low serum for 24 h. After that, cells were switched to the medium containing 10% FBS and 50 M BrdUrd. 24 h later, cells were fixed with 3.7% formaldehyde in phosphate-buffered saline and permeabilized with 0.5% Triton X-100. Before the immunostaining, cells were incubated first with DNase (0.1 units/l, Promega) for 30 min at 37°C.
To determine which phase of the cell cycle is affected by ␤ 1 D integrin, NIH 3T3 cells on coverslips were starved in DMEM with 0.5% FBS for 2 days and then injected with ␤ 1 A or ␤ 1 D cDNA 0, 4, 8, 12, or 16 h after the addition of DMEM with 10% FBS. At least 250 cells were injected with each cDNA. More than 70% of the injected cells expressed the exogenous ␤ 1 A or ␤ 1 D proteins. In preliminary experiments, maximal protein expression was achieved 1-1.5 h after cDNA injection. 50 M BrdUrd was added 18 h after the switch to 10% FBS, and the cells were incubated with BrdUrd for 6 h more. After BrdUrd treatment, cells were washed, fixed, and permeabilized as described above.
Immunostaining of the Transfected and Injected Cells-To visualize simultaneously the transfected (injected) ␤ 1 integrins and nuclear incorporation of BrdUrd, fixed, permeabilized, and DNase-treated cells were coincubated with mAb TS2/16 against human ␤ 1 integrins and anti-BrdUrd mAb (1:100 dilution) for 1 h at 37°C. Rhodamine-labeled donkey anti-mouse IgG (Chemicon, Temecula, CA) was used as secondary antibody to visualize the expressed ␤ 1 integrins at focal adhesions and accumulation of BrdUrd in the nuclei. Coverslips were viewed on a Zeiss Axiophot microscope equipped for epifluorescence. To detect nuclear localization of cyclins A and E in ␤ 1 A-and ␤ 1 Dtransfected NIH 3T3 cells, they were initially treated as described above (see "Cell Proliferation Assay"). The cells were double-stained with mouse mAb TS2/16 and rabbit polyclonal antibodies against cyclins A and E, followed by a mixture of rhodamine-labeled donkey antimouse IgG and fluorescein-labeled goat anti-rabbit IgG (Chemicon). 120 ␤ 1 A-and ␤ 1 D-expressing NIH 3T3 cells were counted for both cyclin E and cyclin A expression.
In some experiments, intracellular localization of the endogenous ␤ 1 A integrin was examined in NIH 3T3 cells expressing human ␤ 1 D. In this case cells were incubated first with a mixture of mouse mAb TS2/16 against human ␤ 1 integrin, mouse mAb against BrdUrd, and hamster mAb HM␤ 1 -1 specific for mouse ␤ 1 integrin (PharMingen). This was followed by coincubation with rhodamine-conjugated donkey antimouse IgG and fluorescein-labeled donkey anti-hamster IgG (Chemicon).
MAP Kinase Assays-Activation of MAP kinases in ␤ 1 A-and ␤ 1 Dtransfected C2C12 cells was studied as reported earlier (6, 9, 10, 16, 32, 33) , with some modifications. Briefly, cells transfected with human ␤ 1 A and ␤ 1 D cDNAs were trypsinized on the day after transfection. The remaining trypsin was inhibited with 0.5 mg/ml soybean trypsin inhibitor, and cells were washed several times in serum-free medium. Cells in DMEM, containing 2% bovine serum albumin, were plated on bacterial Petri dishes, precoated with purified TS2/16 mAb against the transfected ␤ 1 integrins, for 2 h at 37°C. Unbound cells were washed out, and the adherent cells expressing human ␤ 1 A or ␤ 1 D integrins were lysed either in 1% SDS or in buffer containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 150 mM NaCl, 50 mM HEPES, pH 7.5, with 1 mM sodium orthovanadate, 50 mM NaF, 1 mM p-nitrophenyl phosphate, 20 nM calyculin A, 10 g/ml aprotinin, 10 g/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride. Protein concentration in the samples was determined using Pierce BCA Protein Assay Reagent. Samples in 1% SDS (25 g each) were used directly for SDS-polyacrylamide gel electrophoresis and subsequent immunoblotting with polyclonal antibody against activated (dually phosphorylated) MAP kinases (Promega). 0.5 mg of cell lysates in 1% Nonidet P-40, 0.5% sodium deoxycholate buffer were used for immunoprecipitation with sc-93 anti-MAP kinase antibody (Santa Cruz Biotechnology) followed by immune kinase reaction with [␥- 32 P]ATP and the exogenous substrate myelin basic protein (MBP). Phosphorylated MBP bands were analyzed by SDS electrophoresis and autoradiography (6, 16) . Metabolic Labeling, Immunoprecipitation, and ImmunoblottingCultured NIH 3T3 fibroblasts (wild-type or expressing exogenous Ha-(12R)Ras) were metabolically labeled with 0.1 mCi/ml Tran 35 S-label (ICN Biomedicals, Irvine, CA) in methionine-and cysteine-free medium for 12 h at 37°C. After the labeling, cells were washed 3 times with phosphate-buffered saline and lysed on ice for 3 min with RIPA buffer (150 mM NaCl, 50 mM Tris-Cl, pH 7.5; containing 0.1% SDS, 1% Triton X-100 and 0.5% sodium deoxycholate). ␣ 1 , ␣ 2 , ␣ 3 , ␣ 5 , and the endogenous mouse ␤ 1 integrins were immunoprecipitated using the specific antibodies against these subunits. The resulting immunoprecipitates were analyzed by SDS-polyacrylamide gel electrophoresis on 10% gels.
Cultured Ha-(12R)Ras-NIH 3T3 cells expressing human either ␤ 1 A or ␤ 1 D integrins were lysed in RIPA buffer and immunoprecipitated with the antibodies against the endogenous mouse ␣ subunits or TS2/16 mAb against the transfected human ␤ 1 integrins. The immunoprecipitates were extensively washed and boiled in SDS sample buffer. After SDS-polyacrylamide gel electrophoresis, ␤ 1 A and ␤ 1 D isoforms were detected in the immunoprecipitates by immunoblotting with the isoform-specific antibodies (16, 17) .
RESULTS
In our preliminary experiments we were not able to obtain stable expression of ␤ 1 D in normal myoblasts, including mouse C2C12 cells or normal fibroblasts, such as REF 52 or NIH 3T3 cell lines, suggesting that this integrin might directly affect cell growth. To examine this possibility, we first microinjected either ␤ 1 A or ␤ 1 D cDNAs into the nuclei of these cells. The injected cells were serum-starved, then treated for 24 h with BrdUrd in serum-containing medium, and finally stained for both human ␤ 1 integrin and BrdUrd incorporation (Fig. 1) . No nuclear staining was seen in ␤ 1 A-and ␤ 1 D-injected cells with anti-␤ 1 integrin TS2/16 mAb alone (not shown). Whereas the majority of untransfected and ␤ 1 A-transfected cells displayed bright nuclear staining with anti-BrdUrd mAb (Fig. 1, A and C,  arrows) , most ␤ 1 D-transfected C2C12, REF 52, and NIH 3T3 cells did not incorporate BrdUrd into the nuclei (Fig. 1, B, D,  and E, arrowheads) . This indicated that ␤ 1 D caused growth arrest in these cell types. In the injected cells, ␤ 1 D colocalized with the endogenous ␤ 1 A integrin at focal adhesions but did not cause a displacement or relocalization of ␤ 1 A from these sites (Fig. 1, E and F) . Therefore, we concluded that the observed inhibition of cell proliferation in ␤ 1 D-transfected cells was caused by the expression of ␤ 1 D integrin rather than the lack of the common ␤ 1 A isoform at cell-matrix contacts.
Transient transfection of ␤ 1 A and ␤ 1 D cDNAs in C2C12, REF 52, and NIH 3T3 cells resulted in similar expression levels of these integrins on the cell surface as determined by flow cytometry with TS2/16 mAb (Table I) . Quantitation of the growth inhibitory effect mediated by ␤ 1 D in the transfectants showed that in the presence of this integrin only ϳ20% of C2C12 myoblasts ( Fig. 2A) and ϳ14% of REF 52 fibroblasts (Fig. 2B) were entering the S phase, whereas more than 75% of ␤ 1 A transfectants were progressing into the cell cycle under conditions of this assay. Because the efficiency of cell growth arrest depends on the level of the exogenous ␤ 1 D, the few proliferating ␤ 1 D-transfected cells might represent a subpopulation of the transfectants with the lower level of ␤ 1 D expression. These results show that proliferation of normal myoblasts and fibroblasts is drastically inhibited by ␤ 1 D integrin.
Analysis of MAP kinase activation in ␤ 1 A-and ␤ 1 D-transfected C2C12 cells was first performed in the absence of exogenous growth factors in cells adherent to the substrate specifically via the expressed integrin (Fig. 3, A and D) . ␤ 1 Aexpressing cells displayed high levels of adhesion-dependent MAP kinase activation measured by both immunoblotting and immune complex kinase assays (Fig. 3, A and D; a and aЈ) . In contrast, MAP kinase activity in the adherent ␤ 1 D transfectants did not differ from the basal levels characteristic for these cells in suspension (Fig. 3, A and D; b and bЈ) . Unlike C2C12 cells expressing ␤ 1 D, ␤ 1 D-CHO transfectants exhibited sharp activation of MAP kinases in response to ␤ 1 D-mediated adhesion under the same experimental conditions (Fig. 3, B and E and Ref. 16 ). Therefore, the growth inhibitory effect of ␤ 1 D strongly depends on cellular context and might be suppressed by enhanced activity of certain oncogenes.
In the presence of growth factors both ␤ 1 A-and ␤ 1 D-transfected C2C12 cells displayed higher levels of MAP kinase activation compared with serum-free conditions (Fig. 3, C and F) . However, whereas MAP kinase activation further increased upon adhesion in ␤ 1 A-transfected cells (Fig. 3, C and F; a and  aЈ) , no such enhancement was seen in ␤ 1 D-expressing cells in the presence of serum (Fig. 3, C and F; b and bЈ) . This observation showed that ␤ 1 D down-regulates MAP kinase activity in growth factor-stimulated C2C12 cells as well. Thus, the withdrawal of differentiating myoblasts from the cell cycle in vivo could be attributed at least partly to growth inhibitory effect of
To determine the phase of the cell cycle affected by ␤ 1 D expression, we double-stained both populations of NIH 3T3 transfectants for the expressed human ␤ 1 integrin and either cyclin E or cyclin A (Fig. 4A ). Scoring the ␤ 1 A-and ␤ 1 D-transfected cells for nuclear cyclin staining demonstrated that cyclin E expression did not significantly differ between the two populations. However, the percentage of ␤ 1 A transfectants expressing cyclin A exceeded drastically that of ␤ 1 D-expressing cells. Since the expression of cyclin A occurs specifically during the S phase and ␤ 1 D blocks its appearance in the transfected NIH 3T3 cells, we concluded that ␤ 1 D strongly interferes with the G 1 -S transition. To analyze further the timing of the ␤ 1 Dtriggered cell cycle block, we microinjected ␤ 1 D cDNA at certain time points after serum stimulation of starved cells (Fig.  4B) . DNA synthesis in NIH 3T3 cells became insensitive to inhibition by ␤ 1 D integrin when its cDNA was injected ϳ12 h after serum stimulation. Previously, our estimations showed that the G 1 phase lasts ϳ14 -16 h in this cell type. Together, these two observations demonstrated that ␤ 1 D-mediated growth arrest occurs late in the G 1 phase before the beginning of the S phase.
Previously we were able to select stable ␤ 1 D integrin transfectants of CHO cells (16) and GD25 ␤ 1 integrin-deficient cells (17, 34) , indicating that some cells were able to proliferate in the presence of ␤ 1 D. Since both these cell lines display elevated activity of certain oncogenes, we rationalized that some of them can overcome the ␤ 1 D-triggered cell cycle block. To test this suggestion directly, we transiently transfected ␤ 1 D cDNA into NIH 3T3 cells expressing constitutively activated forms of HaRas and Raf-1 oncogenes (25) (26) (27) (28) . Analysis of cell proliferation by the BrdUrd incorporation assay demonstrated that Ha-(12R)Ras completely abolished the inhibitory effect of ␤ 1 D on cell growth (Fig. 5) . However, (⌬22W)Raf-1 was not able even to diminish this ␤ 1 D-mediated effect. These data showed that certain oncogenes, such as Ha-Ras, overcome the ␤ 1 D-mediated growth arrest, whereas some others, like Raf-1, cannot.
Since integrin ␣ subunits are known to modulate cell growth through differential activation of MAP kinases (13), we asked whether activated Ha-Ras could alter the expression pattern of ␣ subunits in NIH 3T3 transfectants or their association with ␤ 1 D integrin (Fig. 6) . We did not see any detectable changes in the pattern of ␣ subunits associated with ␤ 1 integrin in NIH 3T3 cells transfected with Ha-(12R)Ras compared with the wild-type cells (Fig. 6, A and B) . ␣ 3 and ␣ 5 integrins were the major ␤ 1 -associated ␣ subunits in this cell line. The association of ␤ 1 A and ␤ 1 D integrins with the ␣ subunits was not altered in the corresponding transfectants (Fig. 6, C and D) .
We also wanted to examine which amino acid sequences in ␤ 1 D integrin are required and sufficient for its growth inhibitory function. We therefore created ␤ 1 integrin chimeras by swapping ␤ 1 A and ␤ 1 D cytoplasmic domain sequences (Table  II) . All of these chimeric ␤ 1 A/␤ 1 D integrins were expressed at similar levels on the cell surface and were targeted efficiently to focal adhesions of C2C12 cells, with the exception of chimera 4. None of the C2C12 transfectants expressing these chimeric integrins displayed abnormal adhesion or spreading (not shown). Interestingly, when examined by cell proliferation assay, none of the chimeras was as efficient as ␤ 1 D with regard to growth inhibition (Fig. 7A) . The only chimera that still caused a significant decrease of C2C12 cell proliferation was chimera 2, which lacked only 6 amino acids at the very C terminus of the ␤ 1 D polypeptide (Fig. 7A, Table II ). These data strongly suggest that there is no short amino acid motif within the ␤ 1 D cytoplasmic tail, which is sufficient for this function. Instead, the whole C-terminal half of the cytodomain, encoded by exon D of the ␤ 1 integrin gene (16), appears to be essential for cell growth arrest.
By trying to determine whether the extracellular domain and ligand binding have a role in the growth inhibitory function of ␤ 1 D integrin, we took advantage of earlier engineered chimeric receptors, such as the IL2R-␤ 1 A chimera (30) . This chimera contains the extracellular and transmembrane domains of interleukin 2 receptor and the cytoplasmic domain of ␤ 1 A integrin. By replacing the ␤ 1 A portion of this construct with the cDNA fragment encoding the ␤ 1 D cytoplasmic domain (see "Materials and Methods"), we generated IL2R-␤ 1 D chimeric receptor. Both IL2R-␤ 1 D and IL2R-␤ 1 A chimeras were similarly expressed on the cell surface (Table III) targeted to focal adhesions upon transient expression in C2C12 cells (data not shown). The expression of these two chimeras as well as the wild-type IL2R in C2C12 myoblasts was followed by the analysis of cell proliferation using BrdUrd incorporation method (Fig. 7B) . Our results showed that IL2R-␤ 1 A chimera only slightly decreased proliferation, most likely due to partial disruption of focal adhesions in some of the transfectants expressing high levels of this construct. In contrast, IL2R-␤ 1 D chimeric receptor strongly inhibited cell cycle progression in C2C12 myoblasts (Fig. 7B) .
DISCUSSION
In this work we demonstrated that ␤ 1 D, the muscle-specific variant of the ␤ 1 integrin subunit, inhibits cell cycle progression in normal myoblasts and fibroblasts. Our data reveal a novel function for the ␤ 1 D cytoplasmic domain isoform, which is the predominant ␤ 1 integrin in striated muscles (16) . This growth inhibitory function is specifically ascribable to the alternatively spliced cytoplasmic tail of ␤ 1 D, since the entire cytodomain appears to be both necessary and sufficient for the ␤ 1 D-mediated growth arrest.
␤ 1 D exhibits a dominant-positive effect over the ␤ 1 A isoform due to enhanced interactions with both cytoskeletal and extracellular ligands and displaces the endogenous ␤ 1 A from cellmatrix contacts when expressed in certain cell types (17) . However, in C2C12, REF 52 or NIH 3T3 cells expressing high levels of ␤ 1 D integrin, adhesion, and spreading on various ECM proteins was not visibly affected. Also, our recent data on transiently transfected ␤ 1 D-C2C12 and ␤ 1 D-NIH 3T3 cells indicated that even the cells expressing low amounts of ␤ 1 D and still having the endogenous ␤ 1 A at focal adhesions (Fig. 1, E and F) were unable to proliferate. These observations suggested that the ␤ 1 D-triggered cell cycle block is not caused by the lack of ␤ 1 A at cell-matrix adhesions and consequent loss of ␤ 1 A-mediated signaling but is primarily due to active signaling by ␤ 1 D. Meanwhile, further analysis is needed to elucidate whether this effect is based on the active inhibitory signal by ␤ 1 D or blocking positive adhesion-mediated signaling caused by this integrin variant.
Recently, another ␤ 1 integrin isoform, ␤ 1 C, was shown to generate a strong growth inhibitory signal upon its transient expression in 10T1/2 fibroblasts (23) or CHO cells (24) . Expression of this integrin in vivo is detectable in some blood cells (21) and is up-regulated in tumor necrosis factor-␣-stimulated endothelial cells (24) . No information is available yet concerning the mechanisms of growth arrest mediated by ␤ 1 D and ␤ 1 C isoforms. In both these cases, the cytoplasmic domains alone Table II) were transfected in C2C12 myoblasts, and the percentages of proliferating cells in each population were determined by BrdUrd nuclear staining. B, the cytoplasmic domain of ␤ 1 D integrin is sufficient for the growth inhibitory signal. IL2R as well as IL2R-␤ 1 A and IL2R-␤ 1 D chimeric receptors were transiently expressed in C2C12 cells. Their effects on cell cycle progression was determined using the BrdUrd incorporation assay. Shown are the percentages of cells re-entering the cell cycle in all three cell populations. are sufficient to generate the inhibitory signal, whereas the transmembrane and extracellular domains, and therefore ligand binding, are not required. However, in the case of ␤ 1 C integrin, a short specific motif Gln 795 -Gln 802 is responsible for this function (24) , whereas the entire cytodomain appears to be important for the growth arrest triggered by ␤ 1 D. Another distinction between the mechanisms of growth inhibition by these integrins relates to the fact that ␤ 1 C displays its antiproliferative potential in all the cell types tested so far (23, 24) , although ␤ 1 D growth inhibitory effect is clearly cell type-specific.
Certain oncogenes, as shown here for Ha-(12R)Ras, are able to completely suppress the ␤ 1 D-mediated growth arrest. This explains why we previously were able to obtain stable expression of ␤ 1 D integrin in some cell types that had elevated activity of some oncogenes (CHO and GD25 ␤ 1 -minus cells) but failed to select stable transfectants with other cells displaying a more normal phenotype. This property of ␤ 1 D is also consistent with the fact that some transformed cells of muscle origin, e.g. human rhabdomyosarcoma (RD) cells, proliferate even though expressing significant amounts of ␤ 1 D integrin. 2 Yet, others have shown that expression of c-myc and v-myc oncogenes in C2C12 myocytes does not significantly alter either their differentiation patterns or commitment (irreversible withdrawal from the cell cycle), (35) . Taken together, these observations show that the growth inhibitory effect of ␤ 1 D can be suppressed by some but not all oncogenes.
At present it remains unclear why activated Ha-Ras is able to overcome the growth inhibitory signal from ␤ 1 D whereas activated Raf-1 can not. Most existing models of anchorage-dependent cell growth imply that Ras is positioned upstream from Raf-1 in the integrin-mediated MAP kinase cascade. Also, activated Raf-1 and Ha-Ras have similar transforming activity in NIH 3T3 fibroblasts as judged by cell morphology, growth in soft agar and cytoskeletal changes (26, 28) . However, one recent report showed that integrin-mediated activation of MAP kinases, MEK (MAP kinase kinase) and Raf-1 in NIH 3T3 cells appeared to be independent of Ras (33) . Also, activation of the Raf-1/MAP kinase cascade was shown to be insufficient for Ras transformation of RIE-1 epithelial cells (26) . These recent observations imply that oncogenic Ras triggers certain Raf-independent signals essential for cellular transformation and also reevaluate the roles of Ras and Raf in propagation of adhesionmediated growth signals from integrins to MAP kinases.
Previous analysis of ␤ 1 D expression in mouse myogenic cultures (16) and during mouse embryogenesis 3 showed that the onset of its biosynthesis coincides with the time point of irreversible growth arrest during myocyte differentiation. This indicates that the growth inhibitory properties of ␤ 1 D, demonstrated by transient transfection assays in this study, might be related to the major function of this muscle-specific integrin in vivo. Further work is apparently needed to elucidate the role of specific signaling events in the cell growth arrest mediated by ␤ 1 D integrin.
